Sorrento Therapeutics Inc Sorrento’s (NASDAQ: SRNE) Subsidiary Scilex Gets an sNDA Approval for ZTlido Sorrento Therapeutics, Inc. (NASDAQ: SRNE) disclosed that Scilex Holding has got a supplemental new drug application (sNDA) authorization from the FDA for ZTlido. Scilex is the 99% owned unit of Sorrento Therapeutics.
AbbVie Inc AbbVie (NYSE: ABBV) Announces FDA Extended Review Period for Upadacitinib’s NDA AbbVie Inc. (NYSE: ABBV) declared that FDA has made the decision regarding the supplemental New Drug Application (sNDA) for upadacitinib. FDA has decided that it will extend the review period for sNDA for upadacitinib.